Effects of rapamycin on cell apoptosis in MCF-7 human breast cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 24, 2014, Pages 10659-10663

  Din, Tengku Ahmad Damitri Al Astani Tengku ^a   Seeni, Azman ^b   Khairi, Wirdatul Nur Mohd ^a,c   Shamsuddin, Shaharum ^d   Jaafar, Hasnan ^a  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

^c UNIVERSITI SULTAN ZAINAL ABIDIN   (Malaysia)

^d SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Apoptosis; MCF 7 breast cancer cells; Rapamycin

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; RAPAMYCIN;

ANIMAL; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; HUMAN; MCF 7 CELL LINE; MOUSE; PATHOLOGY; UDDER;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; MAMMARY GLANDS, ANIMAL; MCF-7 CELLS; MICE; SIROLIMUS;

EID: 84923016119     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.24.10659     Document Type: Article

References (29)

1. Aranovich A, Liu Q, Collins T, et al (2012). Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells. Molecular Cell, 45, 754-63.
2. Bateman NW., Sun M, Hood BL, et al (2010). Defining central themes in breast cancer biology by differential proteomics: conserved regulation of cell spreading and focal adhesion kinase. J Proteome Res, 9, 5311-24.
3. Boffa DJ, Luan F, Thomas D, et al (2004). Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res, 10, 293-300.
4. Gelmann EP, Thompson EW, Sommers CL (1992). Invasive and metastatic properties of MCF-7 cells and rasH-transfected MCF-7 cell lines. Int J Cancer, 50, 665-9.
5. Geoerger B, Kerr K, Tang CB, et al (2001). Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res, 61, 1527-32.
6. Gibbons JJ, Abraham RT, Yu K (2009). Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol, 3, 3-17.
7. Grünwald V, DeGraffenried L, Russel D, et al (2002). Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res, 62, 6141-5.
8. Guba M, von Breitenbuch P, Steinbauer M, et al (2002). Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Med, 8, 128-35.
9. Hamelers IH, Van Schaik R, Sussenbach JS, Steenbergh PH (2003). 17β-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor. Cancer Cell Int, 3, 10.
10. Hashemolhosseini S, Nagamine Y, Morley SJ, et al (1998). Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem, 273, 14424-9.
11. Hidalgo M, Rowinsky EK (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 19, 6680-6.
12. Hosoi H, Dilling MB, Shikata T, et al (1999). Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res, 59, 886-94.
13. Huang S, Liu LN, Hosoi H, et al (2001). p53/p21CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin. Cancer Res, 61, 3373-81.
14. Idris FM, Mansor WNAW, Irfan M, Jalal A, Jaafar H (2014). Rapamycin and PF4 induce apoptosis by upregulating Bax and down-regulating survivin in MNU-induced breast cancer. Asian Pac J Cancer Prev, 15, 3939-44.
15. Kawamata S, Sakaida H, Hori T, et al (1998). The upregulation of p27Kip1 by rapamycin results in G1 arrest in exponentially growing T-cell lines. Blood, 91, 561-9.
16. Khemapech N, Pitchaiprasert S, Triratanachat S (2012). Prevalence and clinical significance of mammalian target of rapamycin phosphorylation (p-mTOR) and vascular endothelial growth factor (VEGF) in clear cell carcinoma of the ovary. Asian Pac J Cancer Prev, 13, 6357-62.
17. Lai D, Ho KC, Hao Y, Yang X (2011). Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res, 71, 2728-38.
18. Law BK (2005). Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol, 56, 47-60.
19. Mahalati K, Kahan BD (2001). Clinical pharmacokinetics of sirolimus. Clin Pharmacokinetics, 40, 573-85.
20. Noh WC, Mondesire WH, Peng J, et al (2004). Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res, 10, 1013-23.
21. Rathmell WK, Wright TM, Rini BI (2005). Molecularly targeted therapy in renal cell carcinoma. Expert Rev Anticancer Ther, 5, 1031-40.
22. Rizzieri DA, Feldman, E., DiPersio, J. F, et al (2008). A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res, 14, 2756-62.
23. Sykes SM, Lane SW, Bullinger L, et al (2011). AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell, 146, 697-708.
24. Soule H, Vazquez J, Long A, Albert S, Brennan M (1973). A human cell line from a pleural effusion derived from a breast carcinoma. J National Cancer Inst, 51, 1409-16.
25. Thimmaiah KN, Easton JB, Houghton PJ (2010). Protection from rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling. Cancer Res, 70, 2000-9.
26. Wang Y, Wang X, Zhao H, Liang B, Du Q (2012). Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. J Chemotherapy, 24, 348-57.
27. Wiedmann MW, Caca K (2005). Molecularly targeted therapy for gastrointestinal cancer. Current Cancer Drug Targets, 5, 171-93.
28. Yaacob NS, Nasir R, Norazmi MN (2013). Influence of 17β-estradiol on 15-deoxy-Δ12, 14 prostaglandin J2-induced apoptosis in MCF-7 and MDA-MD-231 cells. Asian Pac J Cancer Prev, 14, 6761-7.
29. Yu K, Toral-Barza L, Discafani C, et al (2001). mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocrine-Related Cancer, 8, 249-58.